Broomfield, CO, United States of America

Brett Joseph Prigaro

This inventor holds 5 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Array Biopharma Inc.. Active years: 2022-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brett Joseph Prigaro. Retrieved from https://idiyas.com/inventor/brett-joseph-prigaro

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 12.0

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Broomfield, CO (US) (2022 - 2023)
Boulder, CO (US) (2022 - 2023)
Indianapolis, IN (US) (2024)

Company Filing History:

5 out of 333

Array Biopharma Inc.

patents

Years Active: 2022-2024

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

2. 11634409 - Compounds for the treatment of BRAF-associated diseases and disorders (2023-04-25),

3. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

4. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

5. 11414404 - Compounds for the treatment of BRAF-associated diseases and disorders (2022-08-16),

Title: Brett Joseph Prigaro: Innovator in Pharmaceutical Compounds

Introduction

Brett Joseph Prigaro is a notable inventor based in Broomfield, Colorado. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific kinases associated with various diseases. With a total of five patents to his name, Prigaro's work is instrumental in advancing medical treatments.

Latest Patents

Prigaro's latest patents include innovative compounds designed as RET kinase inhibitors. These compounds, described by the Formula (I), are effective in treating and preventing diseases associated with RET kinase, including RET-associated disorders. Another significant patent involves compounds for the treatment of BRAF-associated diseases and disorders, which are crucial for addressing both malignant and benign tumors linked to BRAF mutations.

Career Highlights

Brett Joseph Prigaro is currently employed at Array Biopharma Inc., where he continues to push the boundaries of pharmaceutical research. His work has been pivotal in developing new therapeutic options for patients suffering from complex diseases.

Collaborations

Prigaro collaborates with esteemed colleagues such as Andrew T Metcalf and David A Moreno, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Brett Joseph Prigaro's contributions to the field of pharmaceuticals through his patents and collaborative efforts highlight his role as a key innovator. His work continues to pave the way for advancements in medical treatments, benefiting countless patients.

Profile summary based on public USPTO records.